SMARCA2 and neoplasm: As far as it concerns BrM, the presence of inhibitory receptors should be analyzed in the context of each tumor type, along with all the known mechanisms of resistance, but in this case, there are clinical evidences that patients with brain metastases can benefit from ICI (immune checkpoint inhibitor) treatment, especially melanoma (37).